HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models

The anti-HER2 antibody pertuzumab inhibits HER2 dimerization and affects HER2/HER3 dimer formation and signaling. As HER3 and its ligand neuregulin are implicated in pancreatic tumorigenesis, we investigated whether HER3 expression could be a predictive biomarker of pertuzumab efficacy in HER2(low)-...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, GaëLle, ChardèS, Thierry, Gaborit, NadèGe, Mollevi, Caroline, Leconet, Wilhem, Robert, Bruno, Radosevic-Robin, Nina, Penault-Llorca, FréDéRique, Gongora, CéLine, Colombo, Pierre-Emmanuel, Lazrek, Yassamine, Bras-Goncalves, Rui, Savina, Ariel, Azria, David, Bazin, Hervé, PèLegrin, André, Larbouret, Christel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196190/
https://www.ncbi.nlm.nih.gov/pubmed/25216528

Ejemplares similares

Ejemplares similares